By Lewis Jackson
SYDNEY, Jan 24 (Reuters) - Australia's oldest listed
investment firm is finding beaten-down lithium shares are
starting to look like buys, with the sector's downturn
reminiscent of the hasty selling in healthcare stocks caused by
weight-loss drug Ozempic, its top executive said.
Founded in 1928, Australian Foundation Investment Company
(AFIC) AFI.AX manages A$9.3 billion ($6.1 billion) and is a
top-20 shareholder in blue chips such as Macquarie Group
MQG.AX and BHP Group BHP.AX .
AFIC increased its stakes in local healthcare companies CSL
CSL.AX and ResMed RMD.N after a mid-year sell off triggered
by the potential impact of Ozempic and other weight-loss drugs,
according to Managing Director Mark Freeman. Since then shares
in both companies have rebounded.
The company had an A$728 million stake in CSL as of Dec. 29
and is its 12th largest shareholder, according to LSEG data.
With lithium stocks out of favour due to a sustained fall in
prices of the metal used in electric vehicles, Freeman said AFIC
is starting to look at the sector and last year bought a small
position in diversified miner Mineral Resources MIN.AX , which
produces lithium.
"It's like the weight-loss drug thing, you're starting to
get a lot of negative news, the lithium price has come off, so
it's starting to look a lot more interesting to us now," he said
in an interview after reporting results for the half year.
AFIC reported a 16% return for 2023 versus 14% for the
S&P/ASX 200 Accumulation Index .AXJOA . Both figures include
the impact of dividend tax credits.
Profit after tax for the half-year ended Dec. 31 fell to
A$150.1 million, down 8.3% from the previous year's A$163.7
primarily due to the decline in dividends from BHP, Rio Tinto
RIO.AX and Woodside WDS.AX .
($1 = 1.5225 Australian dollars)
(Reporting by Lewis Jackson; Editing by Muralikumar
Anantharaman)
((lewis.jackson@thomsonreuters.com; +61477406822; Reuters
Messaging: @lewjackk))